各位战友AASLD 2011有没有新消息？

StephenW

The only new drug in late-stage clinical trials.

StephenW

REP 9AC - slide from AASLD 2011

cwy121

谁能看懂，讲一下。嘻嘻~

cwy121

上面八名患者，在图中怎么只有七位的？

StephenW

回复 cwy121 的帖子

不知道。论文摘要的资料很少。我认为最重要的事情是：
1。 REP9AC是仍在测试
2。它吸引了其他研究人员的注意

AASLD 2011. An updated progress report of the ongoing phase I/II study on the safety and efficacy of REP 9AC in patients with chronic HBV (CHB) infection is presented.

METHODS: All patients were HBsAg+ with pre-treatment HBV DNA titers between 106 and 1012 copies/ml. Additionally, all patients were shown to have significant liver fibrosis as assessed by pre-treatment liver biopsy. Patients with CHB were subjected to parenteral REP 9AC therapy. Safety and virologic response (HBV DNA [Roche Cobas T], HBsAg, anti-HBs [Immunilite]) were assessed weekly at the trial site/. Off site confirmatory testing of HBsAg, HBeAg, anti-HBs, anti-HBe was conducted using the using the Architect T platform.

RESULTS: Interim data shows that 7 out of 8 patients treated to date have either cleared or have only residual levels of serum HBsAg and anti-HBsAg antibodies have been observed in all patients. Clearance of HBsAg and development of anti-HBs have been observed as early as 7 days and no later than 32 weeks. At the time of abstract submission, 6 out of 7 patients with serum HBsAg reductions had achieved a 3 to 7 log reduction in their HBV DNA titers from pre-treatment levels after 7-13 weeks of treatment. Additionally, three of these seven patients have achieved a complete control of their infection with 20-27 weeks of treatment (HBV DNA < 400cpm-, HBsAg -, HBeAg -, anti-HBs +, anti-HBe +) and are being followed off treatment. These three patients have demonstrated durable immunological control over their infections, having SVRs of 18 months, 12 months and 10.5 months after cessation of treatment.

CONCLUSIONS: These results demonstrate that REP 9AC can rapidly and effectively clear HBsAg from the serum of infected patients. This rapid HBsAg seroclearance appears to allow the restoration of an effective immune response, as evidenced by substantial reductions in serum HBV DNA, seroconversion for HBsAg and HBeAg, and the achievement of SVRs in three patients to date. These results suggest that REP 9AC may become an important new tool in the treatment of chronic hepatitis B.                           

cwy121

回复 StephenW 的帖子

闲的时候我可以帮你翻译一下。。。我在读研呢，对未来的歧视 感到无力啊~

StephenW

回复 cwy121 的帖子

Thanks. What are you studying? Ignore those who discriminate, there are plenty who don't.

非东亚病夫

你给自己太大压力了~~！其实乙肝并没有你想象的那么可怕，不要理会别人怎么看你，很多时候还是先要过好自己这一关~！亏你还读那么多书呢。

cwy121

回复 非东亚病夫 的帖子

不是 关键是找工作的时候受歧视啊，我遭遇过。。。

kennyu

回复 StephenW 的帖子

Thanks,
最近老上不了论坛，似乎网络连接有问题。
今年aasld的abstract里面，组合疗法的文章比较多，结果页都不错。
但是，还是让人感觉激动不起来。